Concerta

Manufactured by Johnson & Johnson

Sourced in Germany, United States

Concerta is a laboratory equipment product manufactured by Johnson & Johnson. It is designed to assist in the analysis and testing of various samples and substances within a controlled laboratory environment. The core function of Concerta is to provide consistent and reliable results for research and development purposes.

Automatically generated - may contain errors

Lab products found in correlation

3 protocols using concerta

Pharmacokinetic Study of Methylphenidate

Check if the same lab product or an alternative is used in the 5 most similar protocols

For each study, 24 subjects were randomized and dosed with Sandoz MPH OCR (Sandoz Development Center Holzkirchen, Holzkirchen, Germany), and with Concerta® (Janssen-Cilag, Neuss, Germany), according to the randomisation schedule. Whole blood samples were collected prior to dosing, and over a period of 24 h following each dose. All blood samples were drawn into pre-chilled (ice-water bath) blood collection tubes (1 × 3 mL) containing ethylenediaminetetraacetic acid (EDTA) K₂. After collection, blood samples were cooled in an ice bath, prior to being centrifuged at 3000 rpm (corresponding to approximately 1900 g) for at least 10 min at approximately 4°C. Two aliquots of at least 0.5 mL (when possible) of plasma were dispensed into polypropylene tubes (as soon as possible), containing a stabilizing solution (EDTA Na₂ 10% w/v, citric acid 10% w/v in water), resulting in a buffer : plasma ratio of 5% v/v and were vortexed. The aliquots were subsequently transferred to a −80°C freezer, pending transfer to the bioanalytical facility.

Schapperer E., Daumann H., Lamouche S., Thyroff-Friesinger U., Viel F, & Weitschies W. (2015). Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag). Pharmacology Research & Perspectives, 3(1), e00072.

+ Open protocol

+ Expand

ADHD Medication Evaluation in Youth

Check if the same lab product or an alternative is used in the 5 most similar protocols

Children and adolescents, between 7 and 15 years old, diagnosed with ADHD in accordance with the DSM-5 criteria [2 ] who had recently started treatment with a prolonged-release formulation of MPH (Concerta^®, Janssen Pharmaceuticals, Inc., Titusville, NJ, USA), were invited to participate in the study. They were recruited between March 2015 and July 2016 from the Neuropediatrics Unit at San Cecilio University Hospital (Granada, Spain), where a primary diagnosis of ADHD was formally made after ruling out other processes leading to attention-deficit/hyperactivity symptoms as per psychometric scales, neuroimaging, blood and neurophysiological tests (electroencephalogram). Informed consent and assent were respectively gathered from parents/guardians and patients before inclusion.
The exclusion criteria were: (1) patients suffering from heart disease; (2) patients diagnosed with glaucoma; (3) presence of neuropsychiatric, metabolic, or endocrine disorders able to justify the current symptoms; (4) current intake of melatonin; (5) concomitant intake of any sleep-disturbing medication except for MPH; and/or ((6) refusal to participate.

Checa-Ros A., Muñoz-Hoyos A., Molina-Carballo A., Viejo-Boyano I., Chacín M., Bermúdez V, & D’Marco L. (2023). Low Doses of Melatonin to Improve Sleep in Children with ADHD: An Open-Label Trial. Children, 10(7), 1121.

+ Open protocol

+ Expand

Randomized Crossover Trial of Long-Acting OROS MPH

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Subjects participated in a 4-week within-subject, randomized, double-blind, placebo-controlled crossover trial of long-acting OROS MPH (Concerta^®, Janssen Pharmaceuticals, Inc., Titusville, NJ), during which children were randomly assigned to one of six dosing schedules (see Froehlich et al.^{27 (link)} for exact dosing schedules) that included three active dosage weeks (18, 27, or 36 mg for children ≤ 25 kg [n = 31]; 18, 36, or 54 mg for children > 25 kg [n = 132]) and one week of placebo. Of note, the dosages used in this study are FDA-approved for use with children ≥6 years old and are identical to the doses examined in other trials examining the impact of OROS MPH on sleep^{15 (link), 22 (link), 23 (link)}. The randomization schemes were randomly selected with the following two rules in place: (1) children could not begin Week 1 of the medication trial on anything higher than 18mg, and (2) children could not go from placebo to 54mg on consecutive weeks. Study medication consisted of identical capsules filled with an inert white powder (placebo) or the prescribed dose of Concerta^® over-encapsulated to preserve the double-blind design. At the end of each week, parents completed the VADPRS^{30 (link)} and Pittsburgh Side Effects Rating Scale (PSERS)³¹ (described below).

Becker S.P., Froehlich T.E, & Epstein J.N. (2016). Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder. Journal of developmental and behavioral pediatrics : JDBP, 37(5), 395-404.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!